These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 19696005)

  • 1. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
    Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
    Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
    Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.
    Fehm T; Jäger W; Krämer S; Sohn C; Solomayer E; Wallwiener D; Gebauer G
    Anticancer Res; 2004; 24(3b):1987-92. PubMed ID: 15274389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases.
    Mihai R; Stevens J; McKinney C; Ibrahim NB
    Eur J Surg Oncol; 2006 Jun; 32(5):511-5. PubMed ID: 16564154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
    St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
    Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
    Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
    Park S; Ahn HK; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Lee JY; Park KT; Ahn JS; Park YH; Im YH
    Oncology; 2012; 82(3):180-7. PubMed ID: 22433564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TPS and CA 15.3 serum values as a guide for treating and monitoring breast cancer patients.
    Giai M; Roagna R; Ponzone R; Biglia N; Sgro L; Perona M; Sismondi P
    Anticancer Res; 1996; 16(2):875-81. PubMed ID: 8687144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process.
    Vincent-Salomon A; Jouve M; Genin P; Fréneaux P; Sigal-Zafrani B; Caly M; Beuzeboc P; Pouillart P; Sastre-Garau X
    Cancer; 2002 Apr; 94(8):2169-73. PubMed ID: 12001113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
    Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
    J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.
    O'Brien DP; Horgan PG; Gough DB; Skehill R; Grimes H; Given HF
    Ann R Coll Surg Engl; 1992 Jan; 74(1):9-11; discussion 12. PubMed ID: 1736805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.
    Lumachi F; Basso SM; Brandes AA; Pagano D; Ermani M
    Anticancer Res; 2004; 24(5B):3221-4. PubMed ID: 15510614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain metastases as late breast cancer relapse. Single institution experience and review of the literature.
    Tomasevic Z; Radosevic-Jelic Lj; Jovanovic D; Milovanovic Z; Tomasevic ZM; Jelic S; Borojevic N
    J BUON; 2009; 14(2):225-8. PubMed ID: 19650170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status.
    Heer K; Kumar H; Read JR; Fox JN; Monson JR; Kerin MJ
    Clin Cancer Res; 2001 Nov; 7(11):3491-4. PubMed ID: 11705867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptors: a marker to increase sensitivity for identifying breast cancer in skin metastasis of unknown primary site.
    Bayer-Garner IB; Smoller B
    Mod Pathol; 2000 Feb; 13(2):119-22. PubMed ID: 10697267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of skin and soft tissue metastases from breast cancer according to subtypes: relationship between EGFR overexpression and skin manifestations.
    Kong JH; Park YH; Kim JA; Kim JH; Yun J; Sun JM; Won YW; Lee S; Kim ST; Cho EY; Ahn JS; Im YH
    Oncology; 2011; 81(1):55-62. PubMed ID: 21934337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of serum HER2 status during clinical course of metastatic breast cancer patients.
    Fehm T; Jäger W; Kraemer S; Sohn C; Solomayer-Meyberg G; Solomayer EF; Kurek R; Wallwiener D; Gebauer G
    Anticancer Res; 2004; 24(6):4205-10. PubMed ID: 15739264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary and secondary distant metastatic breast cancer: two sides of the same coin.
    Güth U; Magaton I; Huang DJ; Fisher R; Schötzau A; Vetter M
    Breast; 2014 Feb; 23(1):26-32. PubMed ID: 24215983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.